Skip to main content

Elevated HDL Cholesterol Linked to Increased Risk for Glaucoma

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 5, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 5, 2025 -- Elevated high-density lipoprotein cholesterol (HDL-C) is associated with an increased risk for glaucoma, while elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglycerides (TG) are associated with a reduced risk, according to a study published online Feb. 4 in the British Journal of Ophthalmology.

Yiyuan Ma, from Sun Yat-sen University in Guangzhou, China, and colleagues conducted a prospective cohort study involving 400,229 participants from the U.K. Biobank to examine the associations of HDL-C, LDL-C, TC, and TG with glaucoma.

The researchers found that 1.72 percent of the participants developed glaucoma during a mean follow-up of 14.44 years. Higher levels of HDL-C were associated with increased glaucoma risk (hazard ratio, 1.05 [95 percent confidence interval, 1.02 to 1.08; P = 0.001] for one standard deviation increase in HDL-C) in multivariate Cox regression, while reduced risk was seen in association with elevated levels of LDL-C, TC, and TG (hazard ratios [95 percent confidence intervals], 0.96 [0.94 to 0.99; P = 0.005], 0.97 [0.94 to 1.00; P = 0.037], and 0.96 [0.94 to 0.99; P = 0.008], respectively). An analysis of associations between the polygenic risk score of serum lipids and glaucoma showed an increased hazard ratio in association with a one-standard deviation increment of HDL-C genetic risk (hazard ratio, 1.05; 95 percent confidence interval, 1.00 to 1.11; P = 0.031). There were no significant associations seen for the polygenic risk scores of LDL-C, TC, and TG with glaucoma.

"HDL cholesterol has been regarded as the 'good cholesterol' for seven decades," the authors write. "However, this study demonstrates that high levels of HDL cholesterol are not consistently associated with a favorable prognostic outcome."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction

MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in...

Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C

FRIDAY, March 28, 2025 -- Combination lipid-lowering therapy (LLT) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with statin...

Olpasiran Leads to Significant Reduction in Oxidized Phospholipids

FRIDAY, Feb. 21, 2025 -- Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained reduction in oxidized...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.